Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Research analysts at Wedbush upped their Q1 2024 earnings per share (EPS) estimates for shares of Janux Therapeutics in a note issued to investors on Tuesday, February 27th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.40) for the quarter, […]
A Janux Therapeutics T cell engager has early clinical data showing improvement in cases of advanced prostate cancer, validating the technology platform that produced the therapy. Janux is now leveraging its soaring stock price to raise $175 million in a stock offering.
Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Wedbush issued their FY2028 earnings per share estimates for shares of Janux Therapeutics in a report issued on Tuesday, February 27th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.45) per share for the year. Wedbush has a “Outperform” rating and a $53.00 […]
Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Analysts at Wedbush issued their FY2028 earnings estimates for shares of Janux Therapeutics in a report issued on Tuesday, February 27th. Wedbush analyst R. Driscoll expects that the company will post earnings per share of ($1.45) for the year. Wedbush has a “Outperform” rating and a $53.00 […]
Old Well Partners LLC bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,300 shares of the company’s stock, valued at approximately $104,000. Several other hedge funds and […]